{"id":83451,"date":"2023-10-23T13:40:18","date_gmt":"2023-10-23T08:10:18","guid":{"rendered":"http:\/\/finservwealth.com\/aurobindo-pharma39s-arm-gets-fda-nod-for-hypogonadism-drug\/"},"modified":"2023-10-23T13:40:18","modified_gmt":"2023-10-23T08:10:18","slug":"aurobindo-pharma39s-arm-gets-fda-nod-for-hypogonadism-drug","status":"publish","type":"post","link":"https:\/\/finservwealth.com\/hi\/aurobindo-pharma39s-arm-gets-fda-nod-for-hypogonadism-drug\/","title":{"rendered":"Aurobindo Pharma#39;s arm gets FDA nod for hypogonadism drug"},"content":{"rendered":"<p> Testosterone Cypionate Injection USP is indicated replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone, Primary hypogonadism (congenital or acquired) and Hypogonadotropic hypogonadism (congenital or acquired).<\/p><div id=\"finse-871214419\" class=\"finse-content finse-entity-placement\"><script async src=\"\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-9118214110898834\" crossorigin=\"anonymous\"><\/script><ins class=\"adsbygoogle\" style=\"display:block;\" data-ad-client=\"ca-pub-9118214110898834\" \ndata-ad-slot=\"\" \ndata-ad-format=\"auto\"><\/ins>\n<script> \n(adsbygoogle = window.adsbygoogle || []).push({}); \n<\/script>\n<\/div>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/aurobindo-pharma39s-arm-gets-fda-nod-for-hypogonadism-drug_17281431.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0Testosterone Cypionate Injection USP is indicated replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone, Primary hypogonadism (congenital or acquired) and Hypogonadotropic hypogonadism (congenital or acquired). Testosterone Cypionate Injection USP is indicated replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone, Primary hypogonadism (congenital or acquired) and Hypogonadotropic hypogonadism (congenital or acquired).\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/aurobindo-pharma39s-arm-gets-fda-nod-for-hypogonadism-drug_17281431.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<p> Testosterone Cypionate Injection USP is indicated replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone, Primary hypogonadism (congenital or acquired) and Hypogonadotropic hypogonadism (congenital or acquired).<\/p>\n<p><a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/aurobindo-pharma39s-arm-gets-fda-nod-for-hypogonadism-drug_17281431.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a><\/p>\n<p>\u200b\u00a0Testosterone Cypionate Injection USP is indicated replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone, Primary hypogonadism (congenital or acquired) and Hypogonadotropic hypogonadism (congenital or acquired). Testosterone Cypionate Injection USP is indicated replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone, Primary hypogonadism (congenital or acquired) and Hypogonadotropic hypogonadism (congenital or acquired).\u00a0\u00a0Moneycontrol Latest News\u00a0<a href=\"https:\/\/www.moneycontrol.com\/news\/buzzing-stocks\/aurobindo-pharma39s-arm-gets-fda-nod-for-hypogonadism-drug_17281431.html\" target=\"_blank\" class=\"feedzy-rss-link-icon\" rel=\"noopener\">Read More<\/a>\u00a0\u00a0<\/p>\n<p><!-- \/wp:html --> Testosterone Cypionate Injection USP is indicated replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone, Primary hypogonadism (congenital or acquired) and Hypogonadotropic hypogonadism (congenital or acquired).<\/p>","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"content-type":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","_themeisle_gutenberg_block_has_review":false,"footnotes":""},"categories":[70],"tags":[],"class_list":["post-83451","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-latest-news"],"jetpack_featured_media_url":"https:\/\/www.moneycontrol.com\/news_image_files\/2021\/200x200\/a\/aurobindi-pharma_200.jpg","_links":{"self":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/83451","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/comments?post=83451"}],"version-history":[{"count":0,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/posts\/83451\/revisions"}],"wp:attachment":[{"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/media?parent=83451"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/categories?post=83451"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/finservwealth.com\/hi\/wp-json\/wp\/v2\/tags?post=83451"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}